惰性B细胞淋巴瘤继发第二肿瘤研究进展

Research Progress in Secondary Tumors of Indolent B-Cell Lymphoma

惰性B细胞淋巴瘤属于非霍奇金淋巴瘤,整体约占非霍奇金淋巴瘤的46%,且有继续增长的趋势。临床上主要表现为肿瘤细胞生长速度和疾病进展缓慢,常于化疗后有残余淋巴结,难以达到完全缓解,易出现复发的特点。随着治疗方式的改变,新的靶向药物的应用,生存率虽然有所提高,但并发第二肿瘤的报道也越来越多,尤其是慢性淋巴细胞白血病和滤泡淋巴瘤发生率较高,第二肿瘤的发生影响了患者的预后并逐渐成为其死亡的主要原因,掌握第二肿瘤的发病率及危险因素,对高危人群做好监测及随访,及早发现并予以合适的治疗方案非常重要。因此本文主要对其继发第二肿瘤的风险及其危险因素进行综述。

Indolent B-cell lymphoma is non-Hodgkin’s lymphoma, accounting for about 46% of all non- Hodgkin’s lymphomas, and is on the rise. Clinically, the main manifestations are slow growth rate of tumor cells and slow progression of the disease, often with residual lymph nodes after chemotherapy, which is difficult to achieve complete remission and easy to relapse. With the application of targeted drugs, the survival rate has been improved, but there are more and more reports of complication of second tumor. Especially chronic lymphocytic leukemia and follicular lymphoma, the occurrence of the second tumor affects the prognosis of patients and gradually becomes the main cause of their death. It is very important to master the incidence and risk factors of the second tumor, monitor and follow up the high-risk population, and make early detection and appropriate treatment plan. Therefore, this paper mainly reviews the risk and risk factors of secondary tumors.